WARNING! More information in the Privacy Policy and the use of cookies Ezetrol Warsaw, June 9, 2016 BIOTON EXPANDS COOPERATION WITH MSD BIOTON SA concluded an agreement with MSD, part of the American concern Merck & Co., under which it will cooperate with MSD in the development of the hypercholesterolemia treatment market with the innovative drug Ezetrol (ezetimibe). Ezetrol is an effective drug in lowering cholesterol and other blood lipids. In the IMPROVE-IT clinical trial involving 18,000 patients, the addition of Ezetrol to standard therapy resulted in a significant reduction in the number of heart attacks and ischemic strokes compared to the statin-only group. In Poland, about 18 million patients suffer from hypercholesterolaemia, of which over 3 million are under standard statin therapy, and yet 80% do not achieve treatment goals. The market of preparations regulating the lipid economy in Poland is worth PLN 500 million. The contract is of great importance to us as it will allow us to further strengthen Bioton's position in the segment of treatment of metabolic diseases. Lipid disorders very often coexist with diabetes and cardiovascular diseases. Therefore, we gain the possibility of introducing innovative and effective therapy into practice based on the resources existing in the Company and the market expertise we have. - said Jerzy Barbachowski, Bioton's Sales and Marketing Director. MSD is one of the seven largest pharmaceutical companies in the world. It offers patients about 100 innovative drugs. Teams of scientists working for MSD have made many groundbreaking discoveries and made it possible to introduce modern therapies in such important areas as e.g. diabetes, cardiovascular diseases, asthma and rheumatoid arthritis, as well as vaccines for adults and children. We have been cooperating with a leading Polish biotechnology company since 2014. So far, the cooperation has included hospital and anti-diabetic drugs. We are glad that we can extend this cooperation with another innovative product - said Erik Plas, Managing Director of MSD in Poland. About company Mission of the company Authorities of BIOTON SA History of BIOTON SA Research and development Quality management Sales targets and global expansion Companies of the BIOTON SA Group Cooperation with the European Union Press office Privacy policy and the use of cookies contact AVAILABILITY OF GENSUPEN Press office Contact for media: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 Contact for investors: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 © 2016 BIOTON SA phone: +48 22 721 40 00 fax: +48 22 721 13 33 bioinfo@bioton.pl